SANICKA is developing clinical decision support tool for the selection and optimization of treatment for patients with acute myeloid leukemia (AML). πCITTM overcomes existing barriers for best use of chemo-immunotherapy (CIT) by assisting hematologist-oncologists with patient-specific selection of standard-of-care and novel leukemia treatments including the optimal drug, along with its dose and schedule for the duration of treatment a priori.
AML is a cancer of the bone marrow and the blood. It progresses rapidly without treatment and affects mostly cells that aren’t fully developed; therefore, these cells can’t carry out their normal functions. AML can be a difficult disease to treat, and researchers are studying new approaches to AML therapy in clinical trials. Learn more
AML in Adults: AML is also called acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia or acute non-lymphocytic leukemia. It is most common in older people Learn more. For information on AML in children, see Leukemia in Children. Learn more
The core of the technology is a mechanistic/deterministic algorithm that uses patient- and tumor-specific data to simulate the response to different treatment alternatives, providing dynamic predictions of the tumor response and patient recovery prior, during and after therapy.
